Sign In
Get Clay Free →

Suggestions

    Christoph Brackmann

    SVP Finance at Moderna

    Christoph Brackmann is a seasoned finance executive who served as Senior Vice President of Finance at Moderna since 2019.12 During his tenure at Moderna, he established and built the finance team, overseeing the rapid expansion of the organization during the COVID-19 pandemic.23

    Prior to Moderna, Brackmann held positions at several prominent pharmaceutical companies:

    • Vice President of Investor Relations and Head of International Finance at Shire plc (acquired by Takeda)23
    • Various financial roles at Eli Lilly and Company2
    • Financial positions at Novartis2

    Brackmann, 51, has recently been appointed as the next Chief Financial Officer of Novocure (NASDAQ: NVCR).12 He will initially join Novocure as a Senior Financial Advisor and transition to the CFO role on January 1, 2025.12

    His educational background includes:

    • Master of Business Administration from SDA Bocconi School of Management, Milan2
    • Bachelor's degree in Business and Economics from the University of Mannheim2

    Brackmann is known for his commercial focus and experience in leading multinational finance functions through periods of growth.4

    Highlights

    Oct 30 · stocktitan.net
    Novocure Appoints Christoph Brackmann as Chief Financial Officer
    Oct 30 · novocure.com
    Novocure Appoints Christoph Brackmann as Chief Financial Officer
    Oct 30 · massdevice.com
    Novocure picks successor for CFO taking over corner office
    Oct 30 · marketwatch.com
    Novocure Names Christoph Brackmann Chief Financial Officer

    Related Questions

    What were Christoph Brackmann's key achievements at Moderna?
    How did Christoph Brackmann contribute to Moderna's financial strategy during the COVID-19 pandemic?
    What is Christoph Brackmann's background before joining Moderna?
    What are Christoph Brackmann's future plans at Novocure?
    How did Christoph Brackmann's experience at Shire plc and Eli Lilly influence his role at Moderna?